Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism

@article{Prior1989SpironolactoneWP,
  title={Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism},
  author={Jerilynn C. Prior and Yvette M. Vigna and D Watson},
  journal={Archives of Sexual Behavior},
  year={1989},
  volume={18},
  pages={49-57}
}
The clinical and hormonal response to 12-month therapy with the antiandrogen, spironolactone, in conjunction with near-physiologic doses of female gonadal steroids in 50 transsexual males, is presented. An unselected referred series of 61 men with the psychiatric diagnosis of transsexualism was treated; 10 subjects who had received previous gonadal surgery and 1 man with Klinefelter's syndrome were excluded. Twenty-seven conventionally treated (CT; high-dose estrogen), age 34.4 ± 10.5 years… Expand
Bicalutamide as an Androgen Blocker With Secondary Effect of Promoting Feminization in Male-to-Female Transgender Adolescents.
TLDR
Bicalutamide may be an alternative to gonadotropin-releasing hormone analogs in transgender male-to-female youth who are also ready to undergo physical transition. Expand
Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial.
TLDR
For feminizing hormone therapy, cyproterone acetate had a higher testosterone suppression efficacy than spironolactone, and this data could be benefit for the transgender health-care providers in medication selection and adverse-effects counseling. Expand
Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy
TLDR
The cyproterone group achieved serum total testosterone concentrations in the female reference range, and as spironolactone may cause feminisation without inhibition of steroidogenesis, it is unclear which anti-androgen is more effective at feminisation. Expand
Efficacy of Sex Steroid Therapy without Progestin or GnRH Agonist for Gonadal Suppression in Adult Transgender Patients.
TLDR
T and E2 therapy are usually effective without progestin or GnRHa therapy to suppress gonadal function in transgender patients and should only be initiated in those patients who do not have adequate gonadal suppression on optimized doses of T or E2 alone. Expand
CLINICAL REVIEW 161 Endocrine Treatment of Transsexual People: A Review of Treatment Regimens, Outcomes, and Adverse Effects
TLDR
The range of treatment used by transsexual people, the rationale behind these, and the expectation from such treatment are discussed, as well as the potential adverse effects of cross-sex hormone treatment of transsexual people. Expand
Psycho-endocrinological aspects in aging males and transsexual persons
TLDR
The Ghent hormonal treatment regimen is described for the first time, to explain the rationale behind it and to evaluate its long-term safety to contribute to the clarification of certain endocrinological and psychoendocrinological aspects in two different clinical contexts. Expand
Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects.
TLDR
The range of treatment used by transsexual people, the rationale behind these, and the expectation from such treatment are discussed, as well as the potential adverse effects of cross-sex hormone treatment of transsexual people. Expand
Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women.
TLDR
It is suggested that spironolactone use in transgender women increases HDL levels and that CPA has the opposite effect, and factors should be considered when choosing between these two antiandrogen agents. Expand
Endocrinologic treatment of gender identity disorders.
TLDR
Physicians caring for patients with transsexualism should have a general knowledge about the diagnosis, available treatment, and monitoring for complications of hormonal therapy. Expand
Endocrinology of Transgender Medicine.
TLDR
Recent data on hormonal treatment of transgender people and its effect on physical, psychological, and mental health is reviewed to provide evidence as to the effect of gender-affirming treatment in the nonbinary population. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 25 REFERENCES
Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism
TLDR
Spironolactone administration appears promising in the therapy of female hirsutism, and acne and seborrhoea improved concomitantly. Expand
Treatment of hirsutism with spironolactone.
TLDR
Spironolactone is a highly effective and safe agent for the treatment of hirsutism through its inhibitory action on both ovarian androgen secretion and peripheral androgen action. Expand
Testicular steroidogenic response to human chorionic gonadotropin of fifteen male transsexuals on chronic estrogen treatment.
TLDR
In spite of the suppressive effects of estrogen, a good response to hCG was noted in such subjects in plasma levels of T, 17 alpha-OHP, and, to a lesser extent, delta 4A even after estrogen administration for 24 months. Expand
Pulmonary embolism in a transsexual man taking diethylstilbestrol.
TLDR
This report describes the occurrence of pulmonary embolism in a normal, healthy man taking estrogens to alter secondary sex characteristics taking diethylstilbestrol, 5 mg every day for two years, in preparation for a sex-reassignment operation. Expand
A novel use of spironolactone: treatment of hirsutism.
TLDR
The data suggest that the antiandrogenic properties of spironolactone render it a suitable agent in the treatment of hirsutism. Expand
The effect of cyproterone acetate alone and in combination with ethinylestradiol on the hypothalamic pituitary adrenal axis, prolactin and growth hormone release in male-to-female transsexuals.
TLDR
The mean growth hormone response was found to be lower in both groups, whereas the mean prolactin response was lower in groups I and II, and the mean cortisol response was higher in group I. Expand
THE FEMINISATION OF GONADOTROPHIN RESPONSES IN INTACT MALE TRANSSEXUALS
TLDR
Male transsexual patients before and after chronic oestrogen therapy given for at least three months to feminise the body habitus before undergoing plastic surgery showed that longterm treatment could transform the normal male pattern of a suppressive eifect of ostrogen on gonadotrophin release to one where the oestrogens increased LH levels and amplified the effect of LHRH on gonadic release. Expand
Effect of medroxyprogesterone acetate (Provera) on the metabolism and biological activity of testosterone.
TLDR
Although there was an over-all decrease in the percentage binding of testosterone for the group, individual responses were variable in degree and did not necessarily correlate with the alterations in the metabolic clearance rate of the steroid. Expand
Squamous metaplasia of the verumontanum with obstruction due to hypertrophy: long-term effects of estrogen on the prostate in an aging male-to-female transsexual.
TLDR
A 30-year-old male-to-female transsexual who had been treated with diethylstilbestrol and Premarin from 1954 to the present, and the interesting effect of the estrogens on the verumontanum and prostate is described and illustrated. Expand
Cerebrovascular occlusion in a transsexual man taking mestranol.
TLDR
A case in which a previously healthy man who was using an oral contraceptive drug developed middle cerebral artery occlusion appears to have been related to estrogen administration, and the occurrence of persistent severe headaches in patients using estrogenic hormones may be a clue to impending cerebrovascular occlusions. Expand
...
1
2
3
...